Literature DB >> 8191407

Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen.

A Greinacher1, B Pötzsch, J Amiral, V Dummel, A Eichner, C Mueller-Eckhardt.   

Abstract

Sera of 34 patients with heparin-associated thrombocytopenia (HAT), giving a positive result in the serotonin release assay (SRA), were assessed in a platelet factor 4 (PF4)/heparin ELISA. Three sera revealing indeterminate results in the SRA and 10 control sera were also investigated. Both tests correlated closely (Kappa 0.742; p = 2.67 x 10(-7)), but one positive serum in the SRA was negative in the pF4/heparin ELISA. We have isolated the HAT antibodies by absorbtion and elution of HAT sera using endothelial cells (HUVEC). Eluates gave similar results as the sera in the PF4/heparin ELISA (Kappa 0.837, p = 9.26 x 10(-9)), and they also correlated very closely with the SRA (Kappa 0.888; p = 8.89 x 10(-10)). This demonstrates that HAT antibodies bind to the same epitope on platelets and on endothelial cells. High heparin concentrations released PF4 in a dose dependent manner from microtiter plates if PF4/heparin, but not if PF4 alone, was covalently linked. Concomitant to the release of PF4, binding of HAT antibodies to PF4/heparin decreased, as indicated by the median optical density (OD) values of OD 0.88 in the presence of buffer compared to OD 0.181 in the presence of 100 IU/ml heparin. The latter values were similar to those obtained when plates were coated with PF4 alone (median OD 0.203). Binding of three eluates was not inhibited by high heparin concentrations and they reacted also with PF4 alone. We conclude that multimolecular PF4/heparin complexes represent the major antigen in HAT. These multimolecular complexes might present several epitopes and form immune complexes after HAT antibody binding which activate platelets via the FcRII. In a few cases, PF4 alone can be recognized by the antibody. However, there is also evidence that other molecules might be involved in some patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8191407

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  61 in total

Review 1.  Laboratory testing for heparin-induced thrombocytopenia.

Authors:  T E Warkentin
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

2.  Thrombocytopenia and fatality associated with olanzapine.

Authors:  Juan Antonio Carrillo; José Antonio González; Guillermo Gervasini; Rosa López; María Angeles Fernández; Guillermo Martín Núñez
Journal:  Eur J Clin Pharmacol       Date:  2004-05-19       Impact factor: 2.953

3.  Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia.

Authors:  Lubica Rauova; Jessica D Hirsch; Teshell K Greene; Li Zhai; Vincent M Hayes; M Anna Kowalska; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2010-08-19       Impact factor: 22.113

4.  Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies.

Authors:  Mizuki Aimoto; Takahisa Yamane; Kazumasa Shiomoto; Chikahiko Sakamoto; Yasuhiro Nakashima; Hideo Koh; Takahiko Nakane; Yasunobu Takeoka; Asao Hirose; Mika Nakamae; Kiyoyuki Hagihara; Yoshiki Terada; Yoshitaka Nakao; Hirohisa Nakamae; Masayuki Hino; Shigeki Miyata
Journal:  Int J Hematol       Date:  2013-10       Impact factor: 2.490

Review 5.  Successful preemptive renal retransplantation in a patient with previous acute graft loss secondary to HIT type II: a case report and review of literature.

Authors:  Mahvish Muzaffar; Xin Li; Shobha Ratnam
Journal:  Int Urol Nephrol       Date:  2011-03-20       Impact factor: 2.370

Review 6.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

7.  [Two surgical case reports showing atypical heparin-induced thrombocytopenia].

Authors:  C Höhnke; S Haas
Journal:  Chirurg       Date:  2007-02       Impact factor: 0.955

8.  Hypersensitivity to nadroparin calcium : case report and review of the literature.

Authors:  Didier G Ebo; Steven E Haine; Margo M Hagendorens; Chris H Bridts; Viviane M Conraads; Ann Vorlat; Chris J Vrints; Luc S De Clerck; Wim J Stevens
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 9.  Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.

Authors:  Connie N Hess; Richard C Becker; John H Alexander; Renato D Lopes
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

10.  High-dose intravenous gamma-globulins for heparin-induced thrombocytopenia: a prompt response.

Authors:  A Winder; Y Shoenfeld; R Hochman; G Keren; Y Levy; A Eldor
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.